Combinational effect of angiotensin receptor blocker and folic acid therapy on uric acid and creatinine level in hyperhomocysteinemia-associated hypertension

Yogendra Singh, Vijaya Paul Samuel, Sunita Dahiya, Gaurav Gupta, Ritu Gillhotra, Anurag Mishra, Mahaveer Singh, Nagaraja SreeHarsha, Shiva Kumar Gubbiyappa, Murtaza M. Tambuwala, Dinesh Kumar Chellappan, Kamal Dua

    Research output: Contribution to journalReview article

    1 Citation (Scopus)

    Abstract

    Homocysteine [HSCH2CH2CH(NH2)COOH] (Hcy) is a sulfur-containing amino acid of 135.18 Da of molecular weight, generated during conversion of methionine to cysteine. If there is a higher accumulation of Hcy in the blood, that is usually above 15 µmol/L, it leads to a condition referred to as hyperhomocysteinemia. A meta-analysis of observational study suggested an elevated concentration of Hcy in blood, which is termed as the risk factors leading to ischemic heart disease and stroke. Further experimental studies stated that Hcy can lead to an increase in the proliferation of vascular smooth muscle cells and functional impairment of endothelial cells. The analyses confirmed some of the predictors for Hcy presence, such as serum uric acid (UA), systolic blood pressure, and hematocrit. However, angiotensin-converting enzyme inhibitors angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) alone are inadequate for controlling UA and creatinine level, although the addition of folic acid may be beneficial in hypertensive patients who are known to have a high prevalence of elevated Hcy. We hypothesized that combination therapy with an ARB (olmesartan) and folic acid is a promising treatment for lowering the UA and creatinine level in hyperhomocysteinemia-associated hypertension.

    LanguageEnglish
    Pages715-719
    Number of pages5
    JournalBiotechnology and Applied Biochemistry
    Volume66
    Issue number5
    Early online date17 Jul 2019
    DOIs
    Publication statusPublished - 1 Sep 2019

    Fingerprint

    Hyperhomocysteinemia
    Angiotensin Receptor Antagonists
    Uric Acid
    Folic Acid
    Creatinine
    Hypertension
    Angiotensin-Converting Enzyme Inhibitors
    Acids
    Blood
    Blood Pressure
    Sulfur Amino Acids
    Endothelial cells
    Blood pressure
    Homocysteine
    Vascular Smooth Muscle
    Hematocrit
    Sulfur
    Methionine
    Enzymes
    Smooth Muscle Myocytes

    Keywords

    • angiotensin receptor blocker
    • creatinine
    • folic acid
    • homocysteine
    • hyperhomocysteinemia
    • hypertension

    Cite this

    Singh, Yogendra ; Samuel, Vijaya Paul ; Dahiya, Sunita ; Gupta, Gaurav ; Gillhotra, Ritu ; Mishra, Anurag ; Singh, Mahaveer ; SreeHarsha, Nagaraja ; Gubbiyappa, Shiva Kumar ; Tambuwala, Murtaza M. ; Chellappan, Dinesh Kumar ; Dua, Kamal. / Combinational effect of angiotensin receptor blocker and folic acid therapy on uric acid and creatinine level in hyperhomocysteinemia-associated hypertension. In: Biotechnology and Applied Biochemistry. 2019 ; Vol. 66, No. 5. pp. 715-719.
    @article{5960f20034f64b2da2dcb3bb5edd59d9,
    title = "Combinational effect of angiotensin receptor blocker and folic acid therapy on uric acid and creatinine level in hyperhomocysteinemia-associated hypertension",
    abstract = "Homocysteine [HSCH2CH2CH(NH2)COOH] (Hcy) is a sulfur-containing amino acid of 135.18 Da of molecular weight, generated during conversion of methionine to cysteine. If there is a higher accumulation of Hcy in the blood, that is usually above 15 µmol/L, it leads to a condition referred to as hyperhomocysteinemia. A meta-analysis of observational study suggested an elevated concentration of Hcy in blood, which is termed as the risk factors leading to ischemic heart disease and stroke. Further experimental studies stated that Hcy can lead to an increase in the proliferation of vascular smooth muscle cells and functional impairment of endothelial cells. The analyses confirmed some of the predictors for Hcy presence, such as serum uric acid (UA), systolic blood pressure, and hematocrit. However, angiotensin-converting enzyme inhibitors angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) alone are inadequate for controlling UA and creatinine level, although the addition of folic acid may be beneficial in hypertensive patients who are known to have a high prevalence of elevated Hcy. We hypothesized that combination therapy with an ARB (olmesartan) and folic acid is a promising treatment for lowering the UA and creatinine level in hyperhomocysteinemia-associated hypertension.",
    keywords = "angiotensin receptor blocker, creatinine, folic acid, homocysteine, hyperhomocysteinemia, hypertension",
    author = "Yogendra Singh and Samuel, {Vijaya Paul} and Sunita Dahiya and Gaurav Gupta and Ritu Gillhotra and Anurag Mishra and Mahaveer Singh and Nagaraja SreeHarsha and Gubbiyappa, {Shiva Kumar} and Tambuwala, {Murtaza M.} and Chellappan, {Dinesh Kumar} and Kamal Dua",
    year = "2019",
    month = "9",
    day = "1",
    doi = "10.1002/bab.1799",
    language = "English",
    volume = "66",
    pages = "715--719",
    journal = "Biotechnology and Applied Biochemistry",
    issn = "0885-4513",
    number = "5",

    }

    Singh, Y, Samuel, VP, Dahiya, S, Gupta, G, Gillhotra, R, Mishra, A, Singh, M, SreeHarsha, N, Gubbiyappa, SK, Tambuwala, MM, Chellappan, DK & Dua, K 2019, 'Combinational effect of angiotensin receptor blocker and folic acid therapy on uric acid and creatinine level in hyperhomocysteinemia-associated hypertension', Biotechnology and Applied Biochemistry, vol. 66, no. 5, pp. 715-719. https://doi.org/10.1002/bab.1799

    Combinational effect of angiotensin receptor blocker and folic acid therapy on uric acid and creatinine level in hyperhomocysteinemia-associated hypertension. / Singh, Yogendra; Samuel, Vijaya Paul; Dahiya, Sunita; Gupta, Gaurav; Gillhotra, Ritu; Mishra, Anurag; Singh, Mahaveer; SreeHarsha, Nagaraja; Gubbiyappa, Shiva Kumar; Tambuwala, Murtaza M.; Chellappan, Dinesh Kumar; Dua, Kamal.

    In: Biotechnology and Applied Biochemistry, Vol. 66, No. 5, 01.09.2019, p. 715-719.

    Research output: Contribution to journalReview article

    TY - JOUR

    T1 - Combinational effect of angiotensin receptor blocker and folic acid therapy on uric acid and creatinine level in hyperhomocysteinemia-associated hypertension

    AU - Singh, Yogendra

    AU - Samuel, Vijaya Paul

    AU - Dahiya, Sunita

    AU - Gupta, Gaurav

    AU - Gillhotra, Ritu

    AU - Mishra, Anurag

    AU - Singh, Mahaveer

    AU - SreeHarsha, Nagaraja

    AU - Gubbiyappa, Shiva Kumar

    AU - Tambuwala, Murtaza M.

    AU - Chellappan, Dinesh Kumar

    AU - Dua, Kamal

    PY - 2019/9/1

    Y1 - 2019/9/1

    N2 - Homocysteine [HSCH2CH2CH(NH2)COOH] (Hcy) is a sulfur-containing amino acid of 135.18 Da of molecular weight, generated during conversion of methionine to cysteine. If there is a higher accumulation of Hcy in the blood, that is usually above 15 µmol/L, it leads to a condition referred to as hyperhomocysteinemia. A meta-analysis of observational study suggested an elevated concentration of Hcy in blood, which is termed as the risk factors leading to ischemic heart disease and stroke. Further experimental studies stated that Hcy can lead to an increase in the proliferation of vascular smooth muscle cells and functional impairment of endothelial cells. The analyses confirmed some of the predictors for Hcy presence, such as serum uric acid (UA), systolic blood pressure, and hematocrit. However, angiotensin-converting enzyme inhibitors angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) alone are inadequate for controlling UA and creatinine level, although the addition of folic acid may be beneficial in hypertensive patients who are known to have a high prevalence of elevated Hcy. We hypothesized that combination therapy with an ARB (olmesartan) and folic acid is a promising treatment for lowering the UA and creatinine level in hyperhomocysteinemia-associated hypertension.

    AB - Homocysteine [HSCH2CH2CH(NH2)COOH] (Hcy) is a sulfur-containing amino acid of 135.18 Da of molecular weight, generated during conversion of methionine to cysteine. If there is a higher accumulation of Hcy in the blood, that is usually above 15 µmol/L, it leads to a condition referred to as hyperhomocysteinemia. A meta-analysis of observational study suggested an elevated concentration of Hcy in blood, which is termed as the risk factors leading to ischemic heart disease and stroke. Further experimental studies stated that Hcy can lead to an increase in the proliferation of vascular smooth muscle cells and functional impairment of endothelial cells. The analyses confirmed some of the predictors for Hcy presence, such as serum uric acid (UA), systolic blood pressure, and hematocrit. However, angiotensin-converting enzyme inhibitors angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) alone are inadequate for controlling UA and creatinine level, although the addition of folic acid may be beneficial in hypertensive patients who are known to have a high prevalence of elevated Hcy. We hypothesized that combination therapy with an ARB (olmesartan) and folic acid is a promising treatment for lowering the UA and creatinine level in hyperhomocysteinemia-associated hypertension.

    KW - angiotensin receptor blocker

    KW - creatinine

    KW - folic acid

    KW - homocysteine

    KW - hyperhomocysteinemia

    KW - hypertension

    UR - http://www.scopus.com/inward/record.url?scp=85073665412&partnerID=8YFLogxK

    U2 - 10.1002/bab.1799

    DO - 10.1002/bab.1799

    M3 - Review article

    VL - 66

    SP - 715

    EP - 719

    JO - Biotechnology and Applied Biochemistry

    T2 - Biotechnology and Applied Biochemistry

    JF - Biotechnology and Applied Biochemistry

    SN - 0885-4513

    IS - 5

    ER -